What is ARDX's health score?

ARDELYX, INC. (ARDX) has a TradeApes health score of 48 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ARDX's estimated fair value?

Based on our 5-year discounted cash flow model, ARDELYX, INC.'s estimated fair value is $4.04 per share, representing a -25.2% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is ARDX undervalued or overvalued?

Our model currently rates ARDX as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ARDX... Refresh in a moment for the full analysis.

ARDELYX, INC. (ARDX)

Healthcare Overvalued low mixed

$5.4

Updated: 2026-06-05

TradeApes Score

Financial Strength

50 Mixed

Operating Trend

58 Mixed

Relative Value

40 Weak

Capital Allocation

25 Stressed

Risk

70 Healthy

Est. Fair Value $4.04

DCF Upside -25.2%

Sector Rank #2024 of 6705

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.